Cargando…

After TGN1412: Recent developments in cytokine release assays

The failure of regulatory science to keep pace with and support the development of new biological medicines was very publically highlighted in March 2006 when the first-in-man Phase I clinical trial of the immunomodulatory CD28-specific monoclonal antibody (mAb) TGN1412 ended in disaster when all si...

Descripción completa

Detalles Bibliográficos
Autores principales: Stebbings, R., Eastwood, D., Poole, S., Thorpe, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541671/
https://www.ncbi.nlm.nih.gov/pubmed/22967038
http://dx.doi.org/10.3109/1547691X.2012.711783
_version_ 1782255399746928640
author Stebbings, R.
Eastwood, D.
Poole, S.
Thorpe, R.
author_facet Stebbings, R.
Eastwood, D.
Poole, S.
Thorpe, R.
author_sort Stebbings, R.
collection PubMed
description The failure of regulatory science to keep pace with and support the development of new biological medicines was very publically highlighted in March 2006 when the first-in-man Phase I clinical trial of the immunomodulatory CD28-specific monoclonal antibody (mAb) TGN1412 ended in disaster when all six volunteers suffered a life-threatening adverse reaction termed a ‘Cytokine Storm’. The poor predictive value of standard pre-clinical safety tests and animal models applied to TGN1412 demonstrated the need for a new generation of immunotoxicity assays and animal models that are both sensitive and predictive of clinical outcome in man. The non-predictive result obtained from pre-clinical safety testing in cynomolgus macaques has now been attributed to a lack of CD28 expression on CD4(+) effector memory T-cells that therefore cannot be stimulated by TGN1412. In contrast, high levels of CD28 are expressed on human CD4(+) effector memory T-cells, the source of most TGN1412-stimulated pro-inflammatory cytokines. Standard in vitro safety tests with human cells were also non-predictive as they did not replicate in vivo presentation of TGN1412. It was subsequently shown that, if an immobilized therapeutic mAb-based assay or endothelial cell co-culture assay was used to evaluate TGN1412, then these would have predicted a pro-inflammatory response in man. New in vitro assays based on these approaches are now being applied to emerging therapeutics to hopefully prevent a repeat of the TGN1412 incident. It has emerged that the mechanism of pro-inflammatory cytokine release stimulated by TGN1412 is different to that of other therapeutic mAbs, such that standard pro-inflammatory markers such as TNFα and IL-8 are not discriminatory. Rather, IL-2 release and lymphoproliferation are optimal readouts of a TGN1412-like pro-inflammatory response.
format Online
Article
Text
id pubmed-3541671
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Informa Healthcare
record_format MEDLINE/PubMed
spelling pubmed-35416712013-01-10 After TGN1412: Recent developments in cytokine release assays Stebbings, R. Eastwood, D. Poole, S. Thorpe, R. J Immunotoxicol Paper from the 20th Summerschool in Immunotoxicology, Beaune, France, Sept. 26–28, 2011 The failure of regulatory science to keep pace with and support the development of new biological medicines was very publically highlighted in March 2006 when the first-in-man Phase I clinical trial of the immunomodulatory CD28-specific monoclonal antibody (mAb) TGN1412 ended in disaster when all six volunteers suffered a life-threatening adverse reaction termed a ‘Cytokine Storm’. The poor predictive value of standard pre-clinical safety tests and animal models applied to TGN1412 demonstrated the need for a new generation of immunotoxicity assays and animal models that are both sensitive and predictive of clinical outcome in man. The non-predictive result obtained from pre-clinical safety testing in cynomolgus macaques has now been attributed to a lack of CD28 expression on CD4(+) effector memory T-cells that therefore cannot be stimulated by TGN1412. In contrast, high levels of CD28 are expressed on human CD4(+) effector memory T-cells, the source of most TGN1412-stimulated pro-inflammatory cytokines. Standard in vitro safety tests with human cells were also non-predictive as they did not replicate in vivo presentation of TGN1412. It was subsequently shown that, if an immobilized therapeutic mAb-based assay or endothelial cell co-culture assay was used to evaluate TGN1412, then these would have predicted a pro-inflammatory response in man. New in vitro assays based on these approaches are now being applied to emerging therapeutics to hopefully prevent a repeat of the TGN1412 incident. It has emerged that the mechanism of pro-inflammatory cytokine release stimulated by TGN1412 is different to that of other therapeutic mAbs, such that standard pro-inflammatory markers such as TNFα and IL-8 are not discriminatory. Rather, IL-2 release and lymphoproliferation are optimal readouts of a TGN1412-like pro-inflammatory response. Informa Healthcare 2013-01 2012-09-11 /pmc/articles/PMC3541671/ /pubmed/22967038 http://dx.doi.org/10.3109/1547691X.2012.711783 Text en © 2013 Informa Healthcare USA, Inc. http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited.
spellingShingle Paper from the 20th Summerschool in Immunotoxicology, Beaune, France, Sept. 26–28, 2011
Stebbings, R.
Eastwood, D.
Poole, S.
Thorpe, R.
After TGN1412: Recent developments in cytokine release assays
title After TGN1412: Recent developments in cytokine release assays
title_full After TGN1412: Recent developments in cytokine release assays
title_fullStr After TGN1412: Recent developments in cytokine release assays
title_full_unstemmed After TGN1412: Recent developments in cytokine release assays
title_short After TGN1412: Recent developments in cytokine release assays
title_sort after tgn1412: recent developments in cytokine release assays
topic Paper from the 20th Summerschool in Immunotoxicology, Beaune, France, Sept. 26–28, 2011
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541671/
https://www.ncbi.nlm.nih.gov/pubmed/22967038
http://dx.doi.org/10.3109/1547691X.2012.711783
work_keys_str_mv AT stebbingsr aftertgn1412recentdevelopmentsincytokinereleaseassays
AT eastwoodd aftertgn1412recentdevelopmentsincytokinereleaseassays
AT pooles aftertgn1412recentdevelopmentsincytokinereleaseassays
AT thorper aftertgn1412recentdevelopmentsincytokinereleaseassays